AU2006301708B2 - Glycyrrhetinic acid-30-amide derivatives and the uses thereof - Google Patents

Glycyrrhetinic acid-30-amide derivatives and the uses thereof Download PDF

Info

Publication number
AU2006301708B2
AU2006301708B2 AU2006301708A AU2006301708A AU2006301708B2 AU 2006301708 B2 AU2006301708 B2 AU 2006301708B2 AU 2006301708 A AU2006301708 A AU 2006301708A AU 2006301708 A AU2006301708 A AU 2006301708A AU 2006301708 B2 AU2006301708 B2 AU 2006301708B2
Authority
AU
Australia
Prior art keywords
methyl
isoxazol
glycyrrhetinamide
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006301708A
Other languages
English (en)
Other versions
AU2006301708A1 (en
Inventor
Lijun Liu
Xiaowen Ren
Lida Tang
Jianwu Wang
Yuli Wang
Weiren Xu
Jianping Yong
Shijun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Publication of AU2006301708A1 publication Critical patent/AU2006301708A1/en
Application granted granted Critical
Publication of AU2006301708B2 publication Critical patent/AU2006301708B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006301708A 2005-10-14 2006-10-16 Glycyrrhetinic acid-30-amide derivatives and the uses thereof Ceased AU2006301708B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2005100153718A CN100488979C (zh) 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途
CN200510015371.8 2005-10-14
PCT/CN2006/002711 WO2007041969A1 (fr) 2005-10-14 2006-10-16 Dérivés d'acide glycyrrhétinique-30-amide et applications

Publications (2)

Publication Number Publication Date
AU2006301708A1 AU2006301708A1 (en) 2007-04-19
AU2006301708B2 true AU2006301708B2 (en) 2011-06-23

Family

ID=37942322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006301708A Ceased AU2006301708B2 (en) 2005-10-14 2006-10-16 Glycyrrhetinic acid-30-amide derivatives and the uses thereof

Country Status (9)

Country Link
US (1) US7790759B2 (enExample)
EP (1) EP1935892B1 (enExample)
JP (1) JP5286087B2 (enExample)
CN (1) CN100488979C (enExample)
AT (1) ATE477019T1 (enExample)
AU (1) AU2006301708B2 (enExample)
DE (1) DE602006016146D1 (enExample)
ES (1) ES2350053T3 (enExample)
WO (1) WO2007041969A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2522455C2 (ru) * 2009-05-31 2014-07-10 Чиа Тай Тяньцин Фармасьютикал Груп Ко.,Лтд. Способ синтеза производного эфира и глицирретиновой кислоты и соединение сложного эфира дезоксиглицирретиновой кислоты

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229172B (zh) * 2007-12-28 2010-10-27 天津药物研究院 甘草次酸30-酰胺类衍生物的固体分散物、其制备方法和用途
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CN102653550A (zh) * 2011-03-01 2012-09-05 广西壮族自治区药用植物园 甘草次酸的制备及用途
CN102250187B (zh) * 2011-04-25 2013-03-27 北京中海康医药科技发展有限公司 一种甘草次酸衍生物及其制备方法
CN102241726B (zh) * 2011-05-27 2013-06-12 苏州大学 甘草次酸衍生物及其作为抗肿瘤药物的应用
CN102813661B (zh) * 2011-06-09 2014-04-09 天津药物研究院 一种甘草次酸衍生物的用途
TWI424839B (zh) 2011-10-27 2014-02-01 Univ Kaohsiung Medical 18β－甘草次酸衍生物及其用途
CN103102382A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型b及其制备方法
CN103102383A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型a及其制备方法
CN102579462B (zh) * 2012-01-18 2013-05-22 苏州大学 甘草次酸衍生物制备抗炎药物中的应用
CN102838651B (zh) * 2012-09-26 2014-05-28 天津药物研究院 一类齐墩果酸的衍生物及其制备方法和用途
PL3075738T3 (pl) 2013-11-25 2019-09-30 Ini Corporation Pochodna kwasu glicyretynowego i jej zastosowanie
CN107619425A (zh) * 2017-09-21 2018-01-23 南京师范大学 一种尾接有机导向分子的芳基钌配合物及其合成方法和应用
US9896476B1 (en) 2017-09-21 2018-02-20 King Saud University Glycyrrhetic acid derivatives
CN110776549B (zh) * 2019-11-25 2021-06-11 烟台大学 含氮杂环甘草次酸衍生物及其制备方法和抗甲型流感病毒应用
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用
CN118561945A (zh) * 2024-05-22 2024-08-30 厦门稀土材料研究所 18β-甘草次酸酯类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1447162A (en) * 1974-03-12 1976-08-25 Landerlan Sa Lab Triterpene derivatives
GB1516271A (en) * 1976-03-15 1978-06-28 Biorex Laboratories Ltd Glycyrrhetinic acid derivatives
GB2140809A (en) * 1983-06-01 1984-12-05 Biorex Laboratories Ltd New derivatives of glycyrrhetinic acid
DE10307388A1 (de) * 2003-02-21 2004-09-02 Cognis Deutschland Gmbh & Co. Kg Glyzyrrhetinsäureester
AU2004255749B2 (en) * 2003-06-30 2008-12-18 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
CN1257182C (zh) * 2004-04-06 2006-05-24 南开大学 甘草次酸的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2522455C2 (ru) * 2009-05-31 2014-07-10 Чиа Тай Тяньцин Фармасьютикал Груп Ко.,Лтд. Способ синтеза производного эфира и глицирретиновой кислоты и соединение сложного эфира дезоксиглицирретиновой кислоты

Also Published As

Publication number Publication date
ES2350053T3 (es) 2011-01-17
DE602006016146D1 (de) 2010-09-23
EP1935892B1 (en) 2010-08-11
CN100488979C (zh) 2009-05-20
JP5286087B2 (ja) 2013-09-11
US7790759B2 (en) 2010-09-07
US20080214636A1 (en) 2008-09-04
WO2007041969A1 (fr) 2007-04-19
EP1935892A4 (en) 2009-04-01
CN1948332A (zh) 2007-04-18
ATE477019T1 (de) 2010-08-15
AU2006301708A1 (en) 2007-04-19
JP2009511511A (ja) 2009-03-19
EP1935892A1 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
EP1935892B1 (en) Glycyrrhetinic acid-30-amide derivatives and the uses thereof
AU2017242867B9 (en) Vortioxetine pamoic acid salt and crystal form thereof
KR101406727B1 (ko) 아고멜라틴 히드로클로라이드 히드레이트 및 이의 제법
DK149886B (da) Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid
CN107987020B (zh) 3,5-二芳基吡唑或3,4-二芳基吡唑类衍生物及其应用
ES2772682T3 (es) Cristal de imidazooxazina, composición farmacéutica que contiene dicho cristal, y método de producción de dicho cristal
KR101406736B1 (ko) 아고멜라틴 히드로브로마이드 히드레이트 및 이의 제법
JP2022535870A (ja) Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途
CN106957315B (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
EP3006432B1 (en) 2,3-butanediamide epoxide compound and preparation method and use thereof
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
JP7266676B2 (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法
CN111377913B (zh) 9-烷氧基小檗碱盐、合成方法及应用
EP0039919B1 (en) Benzoxazole and benzothiazole derivatives with anti-allergic activity
CN108530439B (zh) 呋喃甲酰胺衍生物及其制备方法与应用
JPH07503002A (ja) Ｎｍｄａアンタゴニストとしてのニトロキノロン誘導体
CN107286149B (zh) N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用
CN109305979B (zh) 4-二甲基氨基苯甲醛在制备na抑制剂中的应用
CN108752360B (zh) 一种治疗小儿腹泻的化合物及其制备方法
CN108864073B (zh) N-噻唑基吡啶甲酰胺衍生物及其制备方法与应用
CN107365308B (zh) N-(5-胡椒基噻唑-2-基)酰胺衍生物及其作为抗肿瘤药的应用
JPH01249759A (ja) イソオキサゾリン−３−オン誘導体およびその用途
WO2016206634A1 (zh) 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
JPH0368557A (ja) ビスべンジルイソキノリン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired